Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Finch Therapeutics Group, Inc. (FNCH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 10-Q/A Quarterly Report for the period ended June 30, 2023 [amend]
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/07/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
06/28/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
06/09/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment to Amended and Restated Certificate of Incorporation",
"Certificate of Amendment to Amended and Restated Certificate of Incorporation"
05/18/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Lease Termination Agreement, by and between the Company and NRL WCS 200 Inner Belt Prop, LLC",
"Lease Termination Agreement, by and between the Company and NRL WCS 200 Inner Belt Prop, LLC"
05/11/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/11/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates"
04/26/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/25/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
04/14/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates SOMERVILLE, Mass.,"
01/26/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
01/24/2023 8-K Quarterly results
01/06/2023 8-K Quarterly results
12/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CDI 38K 46K 115K 461K"
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
Docs: "Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results • Patient dosing underway in PRISM4 Phase 3 trial of CP101 in recurrent CDI • Topline PRISM4 data anticipated in H1 2024 • Anticipated cash runway into Q2 2024 SOMERVILLE, Mass., Nov. 10, 2022 -- Finch Therapeutics Group, Inc. , a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today provided corporate updates and reported financial results for the third quarter ended September 30, 2022. “We are pleased with the tremendous progress our team has made recently to advance the development of our lead program, with patient dosing now underway in our PRISM4 Phase 3..."
09/01/2022 8-K Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits &nbs...
Docs: "Investor Contact:"
08/25/2022 8-K Quarterly results
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
06/03/2022 EFFECT Form EFFECT - Notice of Effectiveness:
05/24/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/16/2022 10-Q Quarterly Report for the period ended March 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy